Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aura Biosciences, Inc. (AURA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 4 Johnson David Michael (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Bought 13,500 shares @ $8.2713, valued at $111.7k
Bought 6,566 shares @ $8.6068, valued at $56.5k
10/02/2023 8-K Quarterly results
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023 BOSTON, MA – August 9, 2023 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights. “As we build momentum across our portfolio, we are happy to welcome Drs. Bruce Brown and A...",
"OTHER SOLID TUMORS OCULAR ONCOLOGY"
06/09/2023 4 Mattessich Antony C. (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 16,000 options to buy @ $12.83, valued at $205.3k
06/09/2023 4 Johnson David Michael (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 16,000 options to buy @ $12.83, valued at $205.3k
06/09/2023 4 PAREKH RAJESH B (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 16,000 options to buy @ $12.83, valued at $205.3k
06/09/2023 4 Srivastava Sapna (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 16,000 options to buy @ $12.83, valued at $205.3k
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melanoma Enrollment Complete in Phase 2 Trial in Choroidal Melanoma Using Suprachoroidal Route of Administration BOSTON, MA – May 11, 2023 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2023, and provided clinical development and operational highlights. “We are encouraged by our recent interactions with the FDA in support of our global Phase 3 trial designed to en...",
"OTHER SOLID TUMORS OCULAR ONCOLOGY"
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration Grants Fast Track Designation for Belzupacap Sarotalocan for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON, MA – March 15, 2023 – Aura Biosciences, Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights. “2023 is off to a..."
02/14/2023 SC 13G EVENTIDE ASSET MANAGEMENT, LLC reports a 6.3% stake in Aura Biosciences, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.8% stake in Aura Biosciences, Inc.
01/23/2023 4 Feder Julie B (CFO) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 48,750 shares @ $0
Granted 75,000 options to buy @ $10.18, valued at $763.5k
01/23/2023 4 De Rosch Mark (COO) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 42,250 shares @ $0
Granted 65,000 options to buy @ $10.18, valued at $661.7k
01/23/2023 4 de los Pinos Elisabet (See Remarks) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 121,875 shares @ $0
Granted 187,500 options to buy @ $10.18, valued at $1.9M
01/23/2023 4 Rich Cadmus (See Remarks) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Granted 34,125 shares @ $0
Granted 52,500 options to buy @ $10.18, valued at $534.5k
01/20/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 4 Johnson David Michael (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Bought 300 shares @ $10, valued at $3k
Bought 96 shares @ $10, valued at $960
Bought 700 shares @ $10.5, valued at $7.4k
Bought 904 shares @ $10.51, valued at $9.5k
01/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate presentation of the Company",
"Corporate presentation of the Company"
12/30/2022 4 Johnson David Michael (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Bought 2,000 shares @ $9.75, valued at $19.5k
Bought 2,000 shares @ $9.75, valued at $19.5k
12/15/2022 4 Johnson David Michael (Director) has filed a Form 4 on Aura Biosciences, Inc.
Txns: Bought 5,000 shares @ $12.37, valued at $61.9k
Bought 5,000 shares @ $12.37, valued at $61.9k
12/15/2022 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.6% stake in Aura Biosciences, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy